Q: What role do/will biosimilars play in Patheon's future? A: Biosimilars are part of the industry's future. We foresee a series of large market biosimilars being approved in the next few years. Cell culture manufacturing processes are more productive now than they were 15 to 20 years ago, and the scale and capacity required to manufacture these has decreased significantly. While biosimilars were historically manufactured in-house, outsourcing is now increasingly gaining favor. Patheon has accumulated expertise and experience working with innovator products for the past 10 years, as well as biosimilars in the past few years, so we are extremely well-positioned to take advantage of this opportunity with biosimilars. Q: What trends do you see driving the pharmaceutical manufacturing industry in the next few years? A : Outsourcing and consolidation will continue to influence the CDMO industry in the coming years.